Clincosm LogoSign in Get a demo

Refractory Multiple Myeloma

Showing 1 - 25 of 105
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma Trial in Boston (Elranatamab)

Not yet recruiting
  • Refractory Multiple Myeloma
  • +2 more
  • Boston, Massachusetts
  • +2 more
Nov 17, 2023

NHL, Multiple Myeloma, Blood Cancer Trial in Minneapolis, Houston, Fairfax (IDP-023, Rituximab, Daratumumab)

Recruiting
  • NHL
  • +6 more
  • Minneapolis, Minnesota
  • +2 more
Nov 7, 2023

Recurrent Multiple Myeloma, Refractory Multiple Myeloma Trial in Columbus (procedure, drug, biological)

Not yet recruiting
  • Recurrent Multiple Myeloma
  • Refractory Multiple Myeloma
  • Biospecimen Collection
  • +9 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 1, 2023

Recurrent Multiple Myeloma, Refractory Multiple Myeloma Trial in Los Angeles (procedure, drug, other)

Not yet recruiting
  • Recurrent Multiple Myeloma
  • Refractory Multiple Myeloma
  • Bone Marrow Aspiration
  • +10 more
  • Los Angeles, California
    Melanie Ayala Ceja
Jul 10, 2023

Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma Trial in Boston (Isatuximab, Belantamab mafodotin, Pomalidomide)

Not yet recruiting
  • Relapsed Cancer
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jun 19, 2023

Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in Miami (Iberdomide, Carfilzomib, Daratumumab)

Not yet recruiting
  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Miami, Florida
    University of Miami
May 31, 2023

Learn How Triple Class Refractory Multiple Myeloma Are Treated

Not yet recruiting
  • Relapse Multiple Myeloma
  • Refractory Multiple Myeloma
    • (no location specified)
    Feb 15, 2023

    Myeloma Multiple, Myeloma, Refractory Multiple Myeloma Trial in Brooklyn, New York (Selinexor, Clarithromycin, Pomalidomide)

    Terminated
    • Myeloma Multiple
    • +2 more
    • Brooklyn, New York
    • +1 more
    Jan 24, 2023

    Elranatamab, Myeloma, Multiple Myeloma Trial in China (Elranatamab)

    Recruiting
    • Elranatamab
    • +10 more
    • Fuzhou, Fujian, China
    • +18 more
    Jan 18, 2023

    Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,

    Recruiting
    • Refractory Multiple Myeloma
    • Relapsed Multiple Myeloma
    • Manufactured Anti-BCMA CAR-T cells
    • +2 more
    • San Francisco, California
      University of California, San Francisco
    Jan 6, 2023

    Multiple Myeloma, Refractory Multiple Myeloma Trial (procedure, drug, radiation)

    Withdrawn
    • Multiple Myeloma
    • Refractory Multiple Myeloma
    • nonmyeloablative allogeneic hematopoietic stem cell transplantation
    • +7 more
    • (no location specified)
    Jan 4, 2023

    Multiple Myeloma, Relapsed Cancer, Refractory Multiple Myeloma Trial (ANV419, Lenalidomide with low-dose dexamethasone,

    Not yet recruiting
    • Multiple Myeloma
    • +4 more
    • (no location specified)
    Nov 29, 2022

    Multiple Myeloma in Relapse, Refractory Multiple Myeloma Trial in China, Taiwan (TJ202 and Dexamethasone)

    Active, not recruiting
    • Multiple Myeloma in Relapse
    • Refractory Multiple Myeloma
    • TJ202 and Dexamethasone
    • Beijing, Beijing, China
    • +17 more
    Oct 17, 2022

    Multiple Myeloma in Relapse, Refractory Multiple Myeloma Trial in China, Taiwan (TJ202, Lenalidomide and Dexamethasone,

    Active, not recruiting
    • Multiple Myeloma in Relapse
    • Refractory Multiple Myeloma
    • TJ202, Lenalidomide and Dexamethasone
    • Lenalidomide and Dexamethasone
    • Beijing, Beijing, China
    • +40 more
    Oct 17, 2022

    Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial in Worldwide (Dexamethasone, Daratumumab, Carfilzomib)

    Completed
    Has Results
    • Relapsed Multiple Myeloma
    • Refractory Multiple Myeloma
    • Boca Raton, Florida
    • +112 more
    Sep 9, 2022

    Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial in United States (REGN5459)

    Active, not recruiting
    • Relapsed Multiple Myeloma
    • Refractory Multiple Myeloma
    • Indianapolis, Indiana
    • +6 more
    Aug 16, 2022

    Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in Milwaukee (Belantamab mafodotin)

    Recruiting
    • Refractory Multiple Myeloma
    • Relapse Multiple Myeloma
    • Belantamab mafodotin
    • Milwaukee, Wisconsin
      Froedtert & the Medical College of Wisconsin
    Aug 3, 2022

    Multiple Myeloma in Relapse, Refractory Multiple Myeloma Trial in Israel (ixazomib-pomalidomide-dexamethasone)

    Recruiting
    • Multiple Myeloma in Relapse
    • Refractory Multiple Myeloma
    • Afula, Israel
    • +7 more
    Jul 10, 2022

    Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial (Rapid Infusion Isatuximab)

    Withdrawn
    • Relapsed Multiple Myeloma
    • Refractory Multiple Myeloma
    • Rapid Infusion Isatuximab
    • (no location specified)
    Jul 3, 2022

    Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in New York (MCARH125, MCARH109)

    Recruiting
    • Multiple Myeloma
    • +2 more
    • MCARH125
    • MCARH109
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Jun 20, 2022

    Relapse Multiple Myeloma, Refractory Multiple Myeloma Trial in Hangzhou (BCMA Targeted CAR T-cells)

    Recruiting
    • Relapse Multiple Myeloma
    • Refractory Multiple Myeloma
    • BCMA Targeted CAR T-cells
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital, Medical College, Zhejiang Univers
    Jun 18, 2022

    Multiple Myeloma, Refractory Multiple Myeloma Trial in Houston (Digital Health Coaching Program, Fitbit)

    Recruiting
    • Multiple Myeloma
    • Refractory Multiple Myeloma
    • Digital Health Coaching Program
    • Fitbit
    • Houston, Texas
      The University of Texas MD Anderson Cancer Center
    Jun 17, 2022

    Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in New York (Daratumumab, Clarithromycin,

    Recruiting
    • Multiple Myeloma
    • +2 more
    • New York, New York
      Weill Cornell Medicine - Multiple Myeloma Center
    Jun 8, 2022

    Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial (Elotuzumab, Selinexor, and Dexamethasone (ESd))

    Withdrawn
    • Relapsed Multiple Myeloma
    • Refractory Multiple Myeloma
    • Elotuzumab, Selinexor, and Dexamethasone (ESd)
    • (no location specified)
    Apr 27, 2022

    Refractory Multiple Myeloma Trial in United States (selinexor, carfilzomib, dexamethasone)

    Recruiting
    • Refractory Multiple Myeloma
    • Scottsdale, Arizona
    • +4 more
    Apr 1, 2022